Despite Positive Data, Can Genocea Build A Market?
This article was originally published in Scrip
Executive Summary
Genocea Biosciences is one step closer to moving its lead candidate into Phase III, but despite positive results, there may not be a strong market for the drug. Unlike the buzz around immunotherapies in oncology, Genocea has not been able to harness that excitement for its non-cancer immunotherapy.